Ganirelix

Drug Profile

Ganirelix

Alternative Names: Antagon; Ganirelix acetate; Ganirest; ORG 37462; Orgalutran; RS 26306

Latest Information Update: 18 Nov 2009

Price : $50

At a glance

  • Originator Roche
  • Developer Merck & Co
  • Class Antihormones; Infertility therapies; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Jan 2009 Launched for Female infertility in Japan (SC)
  • 21 Jul 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top